EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial

Juliana M Bue-Valleskey iD, Christof M Kazda, Chenchen Ma, Jenny Chien, Qianyi Zhang, Emmanuel Chigutsa, William Landschulz, Axel Haupt, Juan P Frias

Diabetes Care · 01.05.2023 · 46 (5) · 1060-1067

DOI: 10.2337/dc22-2396 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 21.03.2023. Verfasst von Juliana M Bue-Valleskey und 8 weiteren Autor:innen. Beteiligte Einrichtung: 1Eli Lilly and Company, Indianapolis, IN. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Basal insulin Fc (BIF) (insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once-weekly basal insulin administration. This phase 2 study assessed the safety and efficacy of BIF versus degludec in insulin-naive patients with type 2 diabetes (T2D) previously treated with oral antihyperglycemic medications. RESEARCH DESIGN AND METHODS During this randomized, parallel, open-label study, 278 insulin-naive patients with T2D were randomly assigned (1:1) to receive BIF once weekly or degludec once daily over the 26-week treatment period. Both groups were titrated to fasting glucose of 80–100 mg/dL (4.4 to <5.6 mmol/L). The primary end point was HbA1c change from baseline to week 26 (noninferiority margin 0.4%). Secondary end points included fasting blood glucose (FBG), six-point glucose profiles, and rate of hypoglycemia. RESULTS After 26 weeks of treatment, BIF demonstrated a noninferior HbA1c change from baseline versus degludec, with a treatment difference of 0.06% (90% CI −0.11, 0.24; P = 0.56). Both BIF and degludec treatment led to significant reductions in FBG from baseline. At week 26, the between-treatment difference for BIF versus degludec was 4.7 mg/dL (90% CI 0.1, 9.3; P = 0.09). The rate of level 2 hypoglycemia was low and not significantly different between treatment groups (BIF 0.22 events/patient/year, degludec 0.15 events/patient/year; P = 0.64); there was no severe hypoglycemia. The occurrence of treatment-emergent adverse events was also similar between BIF and degludec. CONCLUSIONS Once-weekly BIF achieved excellent glycemic control similar to degludec, with no concerning hypoglycemia or other safety findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HypoglycemiaHumansInsulinInsulin GlargineGlycated HemoglobinGlycemic ControlBlood GlucoseHypoglycemic AgentsInsulin, Regular, HumanGlucoseInsulin, Long-Acting

Substanzen

InsulinInsulin GlargineGlycated HemoglobinBlood GlucoseHypoglycemic AgentsInsulin, Regular, HumanGlucoseinsulin degludecInsulin, Long-Acting

Autor:innen und Institutionen

  • 1Eli Lilly and Company, Indianapolis, IN.
  • 2Lilly France, Neuilly sur Seine, France.
  • 3Velocity Clinical Research, Los Angeles, CA.

ORCID-Profile: Juliana M Bue-Valleskey

Förderung

  • Eli Lilly and Company

Zitieren

APA

Bue-Valleskey, J. M., Kazda, C. M., Ma, C., Chien, J., Zhang, Q., Chigutsa, E., Landschulz, W., Haupt, A., & Frias, J. P. (2023). Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial. Diabetes Care, 46(5), 1060-1067. https://doi.org/10.2337/dc22-2396

Vancouver

Bue-Valleskey JM, Kazda CM, Ma C, Chien J, Zhang Q, Chigutsa E, et al. Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial. Diabetes Care. 2023;46(5):1060-1067. doi:10.2337/dc22-2396

BibTeX
@article{BueValleskey2023,
  author = {Bue-Valleskey, Juliana M and Kazda, Christof M and Ma, Chenchen and Chien, Jenny and Zhang, Qianyi and Chigutsa, Emmanuel and Landschulz, William and Haupt, Axel and Frias, Juan P},
  title = {Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial},
  journal = {Diabetes Care},
  year = {2023},
  volume = {46},
  number = {5},
  pages = {1060--1067},
  doi = {10.2337/dc22-2396}
}
Kostenlos starten →